|1.||Oberley-Deegan, Rebecca E: 3 articles (05/2013 - 01/2012)|
|2.||Crapo, James D: 2 articles (01/2012 - 01/2009)|
|3.||Rebouças, Júlio S: 2 articles (07/2009 - 01/2009)|
|4.||Batinić-Haberle, Ines: 2 articles (07/2009 - 01/2009)|
|5.||Spasojević, Ivan: 2 articles (07/2009 - 01/2009)|
|6.||Salvemini, Daniela: 2 articles (07/2009 - 01/2009)|
|7.||El Kasmi, Karim C: 1 article (05/2013)|
|8.||Nozik-Grayck, Eva: 1 article (05/2013)|
|9.||Yeager, Michael E: 1 article (05/2013)|
|10.||Woods, Crystal: 1 article (05/2013)|
10/01/2012 - "The results show that MnTE-2-PyP slowed RM-9 tumor progression and up-regulated immune parameters, but mitigation of the effects of 2 Gy total-body irradiation were minimal."
10/01/2012 - "Treatment of tumor-bearing mice with MnTE-2-PyP alone significantly increased spleen mass relative to body mass; the numbers of splenic white blood cells (WBC) and lymphocytes (B and T), as well as circulating WBC, granulocytes, and platelets, were high compared to one of more of the other groups (P < 0.05). "
10/01/2012 - "Animals treated with MnTE-2-PyP alone had significantly slower tumor growth compared to mice that did not receive the drug (P < 0.05), while radiation alone had no effect. "
10/01/2012 - "C57BL/6 mice were total-body exposed to 2 Gy γ-rays (Co-60), i.e., well below a lethal dose, followed by subcutaneous implantation of 5 × 10(5) RM-9 prostate tumor cells and initiation of MnTE-2-PyP treatment (day 0); interval between each procedure was 1-2 h. "
01/01/2009 - "MnTE-2-PyP did not protect RM-9 prostate tumors against radiation damage and was not toxic under the conditions used. "
01/01/2012 - "Our studies suggest that the major mechanism by which MnTE-2-PyP inhibits airway inflammation is by acting on the DC and suppressing Th2 cell proliferation and activation."
01/01/2012 - "MnTE-2-PyP, a superoxide dismutase mimetic, inhibited OVA-induced airway inflammation in mice suggesting an effect on Th2 responsiveness. "
01/15/2009 - "In another model, carrageenan-induced pleurisy in mice, inflammation was evidenced by increased pleural fluid exudate and neutrophil infiltration and activation: these events were blocked by 0.3 mg/kg MnTE-2-PyP and, to a slightly lesser extent, by 10 mg/kg of either MnTBAP. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2012 - "The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation."
01/01/2012 - "MnTE-2-PyP also protected from erectile dysfunction, a persistent problem regardless of the type of radiation techniques used because the penile neurovascular bundles lay in the peripheral zones of the prostate, where most prostate cancers reside. "
01/01/2012 - "Based on previous studies showing that MnTE-2-PyP, in combination with radiation, further reduces subcutaneous tumor growth, we believe that MnTE-2-PyP represents an excellent radioprotectant in combination radiotherapy for cancer in general and specifically for prostate cancer."
|4.||Asthma (Bronchial Asthma)
01/01/2012 - "The metalloporphyrin antioxidant, MnTE-2-PyP, inhibits Th2 cell immune responses in an asthma model."
01/01/2012 - "The NPSH groups content decreased in group 2. In group 4 this decrease was relatively lower as compared to group 2. The application of MnTE-2-PyP mitigated the effects of oxidative stress in asthma mice model."
01/01/2012 - "To investigate the effects of MnTE-2-PyP on some markers of antioxidant defence system in asthma mice model. "
01/01/2012 - "Antioxidant effect of MnTE-2-PyP on lung in asthma mice model."
|5.||Wounds and Injuries (Trauma)
|2.||Peroxynitrous Acid (Peroxynitrite)